Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Entrada Therapeutics (TRDA) Non Operating Income: 2022-2024

Historic Non Operating Income for Entrada Therapeutics (TRDA) over the last 3 years, with Dec 2024 value amounting to $19.5 million.

  • Entrada Therapeutics' Non Operating Income fell 38.07% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.1 million, marking a year-over-year decrease of 8.45%. This contributed to the annual value of $19.5 million for FY2024, which is 27.97% up from last year.
  • Latest data reveals that Entrada Therapeutics reported Non Operating Income of $19.5 million as of FY2024, which was up 27.97% from $15.2 million recorded in FY2023.
  • Over the past 5 years, Entrada Therapeutics' Non Operating Income peaked at $19.5 million during FY2024, and registered a low of $2.6 million during FY2022.
  • For the 3-year period, Entrada Therapeutics' Non Operating Income averaged around $12.4 million, with its median value being $15.2 million (2023).
  • Data for Entrada Therapeutics' Non Operating Income shows a peak YoY soared of 478.19% (in 2023) over the last 5 years.
  • Yearly analysis of 3 years shows Entrada Therapeutics' Non Operating Income stood at $2.6 million in 2022, then spiked by 478.19% to $15.2 million in 2023, then increased by 27.97% to $19.5 million in 2024.